El.En. SpAELEAF 69 ROC (Joel Greenblatt) % is 33.81% as of Mar. 2026, which is 19% above its 10-year median of 28.45. GuruFocus rates ELEAF with a GF Score™ of 69/100 and a GF Value™ of $12.55 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 840 Medical Devices & Instruments companies, El.En. SpA ranks better than 72.74% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. El.En. SpA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 33.81%.
The historical rank and industry rank for El.En. SpA's ROC (Joel Greenblatt) % or its related term are showing as below:
ELEAF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 18.43 Med: 28.45 Max: 60
Current: 21.89
During the past 13 years, El.En. SpA's highest ROC (Joel Greenblatt) % was 60.00%. The lowest was 18.43%. And the median was 28.45%.
ELEAF's ROC (Joel Greenblatt) % is ranked better than 72.74% of 840
companies
in the Medical Devices & Instruments industry
Industry Median: 4.035
vs ELEAF: 21.89
El.En. SpA's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -2.30% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
El.En. SpA ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for El.En. SpA's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ELEAF vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, El.En. SpA's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
El.En. SpA ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, El.En. SpA's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where El.En. SpA's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 33.81% mean?
El.En. SpA (ELEAF) has a ROC (Joel Greenblatt) % of 33.81% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on El.En. SpA and its competitors. This is 19% above median its historical median of 28.45. Over the past decade, El.En. SpA's ROC (Joel Greenblatt) % has ranged from 18.43 to 60.00. According to the industry distribution chart, El.En. SpA ranks #229 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 27.3%.
Is El.En. SpA's ROC (Joel Greenblatt) % too high?
El.En. SpA's current ROC (Joel Greenblatt) % of 33.81% is 19% above median its 10-year median of 28.45. Over the past 10 years, this metric has ranged from a low of 18.43 to a high of 60.00. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.04. El.En. SpA's value of 33.81% is 737.9% above this industry median. Based on the distribution chart, El.En. SpA ranks #229 out of 840 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, El.En. SpA has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does El.En. SpA's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, El.En. SpA ranks #229 out of 840 companies for ROC (Joel Greenblatt) %. This puts El.En. SpA in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 4.04. El.En. SpA's value of 33.81% is 737.9% above this benchmark. Historically, El.En. SpA's own ROC (Joel Greenblatt) % has ranged from 18.43 to 60.00 over the past decade. While the company's 10-year median is 28.45 vs. the industry median of 4.04, El.En. SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.04, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. El.En. SpA's current ROC (Joel Greenblatt) % of 33.81% is 737.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on El.En. SpA and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. El.En. SpA's current ROC (Joel Greenblatt) % is 33.81%, which is 19% above median its own 10-year median of 28.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is El.En. SpA stock overvalued right now?
Based on GuruFocus' analysis, El.En. SpA (ELEAF) is currently considered Significantly Overvalued. The stock's GF Value™ is $12.55, compared to a current price of $18.50 — trading 47.4% above its estimated fair value. The current ROC (Joel Greenblatt) % is 33.81%, which is 19% above median its 10-year median of 28.45 and 737.9% above the Medical Devices & Instruments industry median of 4.04. El.En. SpA's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For El.En. SpA (ELEAF), the current ROC (Joel Greenblatt) % is 33.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is El.En. SpA (ELEAF) Overvalued in 2026?
Based on GuruFocus' analysis, El.En. SpA stock appears to be overvalued.
The current stock price of $18.50 is trading 47.4% above its estimated GF Value™ of $12.55.
GuruFocus considers El.En. SpA to be Significantly Overvalued.
Key valuation signals for ELEAF:
ROC (Joel Greenblatt) %: 33.81% (19% above median its 10-year median of 28.45)
GF Value™: $12.55 vs. price of $18.50 (47.4% above fair value)
Industry Position: 737.9% above the Medical Devices & Instruments median (#229 of 840)
No single metric tells the full story. See the ELEAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
El.En. SpA is engaged in the research and development, manufacturing, distribution, and sales of laser systems. The company operates in two divisions: medical and industrial. In the medical division, the application of laser is used as a healing treatment for aesthetic, surgical, physiotherapy and dental. Industrial division develops solutions for laser material processing applications through cutting, marking, laser sources and restoration. The company generates the majority of its revenue from the medical division. Geographically, it derives maximum revenue from the Rest of the World.
69GF Score
Get the complete analysis for ELEAF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELEAF has been successfully added to your 
